Naslov
Effects of hormonal therapy on myeloperoxidase expression and activity

Autori
Somborac, Anita ; Sučić, Mirna

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
EMBO Meeting on Cellular Signaling and Molecular Medicine: Program & Abstracts / Đikić, Ivan ; Hušnjak, Koraljka ; Nagy, Vanja - Split, 2008, 133-134

ISBN
978-953-55188-0-8

Skup
EMBO Meeting on Cellular Signaling and Molecular Medicine

Mjesto i datum
Cavtat, Hrvatska, 29.05.2008. - 04.06.2008

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
myeloperoxidase ; neutrophil ; hormone replacement therapy

Sažetak
Background: Myeloperoxidase (MPO) is a major protein in neutrophils, stored in azurophilic granules and released during phagocytosis. It is a hem enzyme that uses the superoxide and hydrogen peroxide generated by the neutrophil oxidative burst to produce hypochlorous acid and other reactive oxidants. Thus, MPO is an important component of the neutrophil’ s antimicrobial function. It was shown that intracellular MPO activity in neutrophils of postmenopausal women is lower in than in females with regular cycles. The aim of this study was to examine the effect of hormonal therapy on MPO expression and activity in women of different age. Materials and Methods: We analysed blood samples of 30 generative age women and 30 postmenopausal women. 8 generative age women were taking contraceptive therapy and 3 postmenopausal women were taking hormone replacement therapy. MPO expression was examined immunocytochemicaly, by using the specific antibody, and MPO activity was examined cytochemicaly, by using the benzidine and H2O2 as substrates. Results: MPO activity and expression results are presented as MPO-score (0-400) and I-MPO-score (0-300), respectively. MPO activity-score was 371.5 (250-395) for generative age women not taking the hormonal therapy ; 382.5 (368-395) for generative age women taking the contraceptive therapy ; 372.5 (270-395) for postmenopausal women not taking hormone replacement therapy ; 355 (345-383) for postmenopausal women taking hormone replacement therapy. I-MPO expression-score was 278.5 (260-299) for generative age women not taking the hormonal therapy ; 290 (278-296) for generative age women taking the contraceptive therapy ; 290 (256-299) for postmenopausal women not taking hormone replacement therapy ; 292 (253-295) for postmenopausal women taking hormone replacement therapy. Conclusions: MPO activity is higher in generative age women taking the contraceptive therapy, than in control ones (p < 0.07). However, MPO activity does not differ significantly in postmenopausal women regardless of hormone replacement therapy. MPO expression does not change depending on therapy. Further examination is needed in order to evaluate duration of the hormone replacement therapy and more postmenopausal women taking the therapy should be included.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA